Just In: Boston Scientific Acquires Nalu Medical for $533 Million
The acquisition brings a novel neurostimulation device into Boston Scientific’s portfolio, expanding its capacity to provide effective solutions for chronic pain management.
Baxdrostat Breakthrough Offers New Hope for Resistant Hypertension
AstraZeneca’s Bax24 Phase III trial demonstrates sustained blood pressure control and a favorable safety profile in patients with treatment-resistant hypertension.
UnitedHealth Scales Back Medicare Advantage Plans in 16 Counties Amid Rising Program Costs and Funding Cuts
Industry analysts warn the move could signal broader consolidation and narrower choices for members in rural areas.
Novo Nordisk Freezes Hiring as Costs Rise Despite Wegovy FDA Approval
Cost-cutting move reflects margin squeeze and rising competition in the weight-loss drug market.
Spurt in Road Accidents Makes Advanced Critical Care Crucial to Save Victims in ‘Golden Hour’
Satellite technology enables emergency responders to pinpoint accident locations with extreme accuracy, even in remote areas.
Sword Health Raises $40M, Pushes IPO to 2028 as Growth Strategy Shifts
Although the company is cash-flow positive, it is postponing a public listing as it focuses on expanding its AI-driven care model and strengthening its position through private funding.
AstraZeneca Deepens China Ties With $5.3 Billion CSPC AI Research Deal
The agreement reflects AstraZeneca’s renewed investment push in China through AI-driven development of therapies for chronic illnesses.
Novo Nordisk Ousts CEO as U.S. Rivals Gain Ground, Drug Pipeline Disappoints
Denmark’s pharmaceutical giant navigates leadership shake-up after Wegovy sales falter and investor confidence wanes.
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight-Loss Trial
Lilly’s Zepbound shows superior results in weight loss, offering a potential edge in the $150 billion obesity drug market.